Rating Change
RBC Capital reiterated its Sector Perform rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on October 08, 2026.
reiterateNASDAQ:SRPT
RBC Capital Reiterates Sector Perform Rating on Sarepta Therapeutics, Inc. (SRPT)
RBC Capital reiterated its Sector Perform rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on October 08, 2026.
At publication ·
What changed
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) · reiterate
- Firm
- RBC Capital
- Rating
- Sector Perform to Sector Perform
- Price at event
- $18.21
- Market capitalization
- $2.1B
At a glance
Key takeaways
- RBC Capital maintained a Sector Perform rating on Sarepta Therapeutics (SRPT) on October 8, 2026.
Market Context
Sarepta Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $18.21 with a market capitalization of $2.1B.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Sarepta Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Sarepta Therapeutics, Inc.
Among the 10 most recent ratings: 2 Buy, 3 Hold, 5 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | RBC Capital | Sector Perform | N/A |
| Oct 05, 2026 | HC Wainwright & Co. | Sell | N/A |
| Sep 30, 2026 | JP Morgan | Neutral | N/A |
| Sep 28, 2026 | Needham | Underperform | N/A |
| Jul 09, 2026 | Piper Sandler | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View SRPT Stock Page
Frequently Asked Questions
What does the Sector Perform rating mean for SRPT?
A rating of Sector Perform from RBC Capital reflects the analyst's outlook on Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SRPT forecast page.